

Table 19.31
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2006-2012

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	78,287	70.4 (70.0 , 70.8)	90.5 (89.5 , 91.5)	79.8 (79.3 , 80.3)	59.9 (59.2 , 60.6)			
1 Hodgkin Lymphoma	6,786	87.3 (86.3 , 88.2)	97.0 (95.4 , 98.0)	92.0 (91.1 , 92.9)	54.2 (49.9 , 58.3)			
2 Non-Hodgkin lymphoma	69,445	69.3 (68.8 , 69.7)	88.6 (87.2 , 89.8)	78.0 (77.4 , 78.6)	60.7 (59.9 , 61.4)			
2(a) Non-Hodgkin lymphoma, B-cell	64,459	69.5 (69.0 , 70.0)	89.1 (87.6 , 90.4)	78.7 (78.0 , 79.3)	61.1 (60.4 , 61.9)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,630	68.6 (66.8 , 70.3)	89.1 (87.4 , 90.5)	39.4 (35.8 , 42.9)	15.4 (10.8 , 20.8)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	57,505	69.5 (69.0 , 70.1)	88.7 (84.7 , 91.8)	80.3 (79.6 , 80.9)	61.3 (60.5 , 62.1)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	12,136	79.9 (78.7 , 81.1)	- (- , -)	89.0 (87.7 , 90.3)	75.0 (73.2 , 76.6)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	11,024	82.3 (81.0 , 83.5)	- (- , -)	91.2 (89.8 , 92.4)	77.5 (75.6 , 79.1)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	30	32.3 (14.9 , 51.2)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.1.3. Mantle-cell lymphoma	1,082	56.9 (52.7 , 61.0)	- (- , -)	70.2 (64.2 , 75.4)	48.4 (42.6 , 54.0)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,208	82.3 (78.3 , 85.6)	- (- , -)	91.5 (87.2 , 94.4)	76.8 (70.9 , 81.6)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	590	77.3 (71.2 , 82.3)	- (- , -)	86.6 (79.1 , 91.5)	71.9 (63.1 , 79.0)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	618	86.8 (81.2 , 90.8)	- (- , -)	95.1 (89.6 , 97.7)	81.3 (72.7 , 87.4)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	15,283	62.0 (61.0 , 63.0)	86.0 (79.8 , 90.4)	74.6 (73.3 , 75.8)	52.2 (50.8 , 53.7)			
2(a) 2.3.1. DLBCL, NOS ^c	15,055	61.6 (60.6 , 62.6)	87.4 (81.1 , 91.7)	74.2 (72.9 , 75.4)	52.2 (50.7 , 53.6)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	27	63.0 (38.7 , 79.9)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.3. Primary effusion lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	197	86.3 (79.7 , 90.9)	- (- , -)	88.2 (81.5 , 92.5)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	616	55.1 (50.6 , 59.3)	90.3 (82.7 , 94.7)	54.3 (48.2 , 60.0)	34.5 (27.0 , 42.2)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	5,061	89.8 (88.1 , 91.2)	- (- , -)	93.9 (92.2 , 95.1)	86.2 (83.4 , 88.5)			
2(a) 2.5.1. Splenic MZL	453	81.8 (74.9 , 87.0)	- (- , -)	87.5 (79.0 , 92.7)	77.2 (66.2 , 85.1)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	3,106	94.0 (92.0 , 95.6)	- (- , -)	96.2 (94.4 , 97.5)	91.7 (87.7 , 94.4)			
2(a) 2.5.3. Nodal MZL	1,502	83.1 (79.8 , 85.9)	- (- , -)	89.7 (85.8 , 92.6)	78.3 (73.2 , 82.5)			
2(a) 2.6. Follicular lymphoma	9,075	88.4 (87.3 , 89.4)	- (- , -)	93.3 (92.3 , 94.2)	82.5 (80.3 , 84.4)			
2(a) 2.7. Hairy-cell leukemia	287	89.9 (82.3 , 94.4)	- (- , -)	97.2 (92.4 , 99.0)	73.2 (54.4 , 85.3)			
2(a) 2.8. Plasma cell neoplasms	13,831	47.3 (46.2 , 48.4)	- (- , -)	62.3 (60.6 , 63.9)	37.0 (35.5 , 38.5)			
2(a) 2.8.1. Plasmacytoma	721	65.4 (60.4 , 70.0)	- (- , -)	80.3 (74.1 , 85.2)	48.5 (40.8 , 55.8)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	13,110	46.3 (45.1 , 47.5)	- (- , -)	61.0 (59.3 , 62.7)	36.5 (34.9 , 38.0)			
2(a) 2.9. Heavy chain disease	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	3,324	70.4 (68.0 , 72.6)	- (- , -)	80.1 (77.1 , 82.8)	65.3 (62.0 , 68.4)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.31 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2006-2012

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
2(b) Non-Hodgkin lymphoma, T-cell	4,297	66.3 (64.5 , 68.0)	85.3 (80.7 , 88.8)	72.2 (70.1 , 74.2)	52.5 (49.0 , 55.8)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	148	67.1 (58.6 , 74.2)	92.0 (81.8 , 96.6)	55.7 (42.7 , 67.0)	- (- , -)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	4,120	66.5 (64.7 , 68.3)	83.7 (78.3 , 87.9)	73.2 (71.0 , 75.2)	53.0 (49.6 , 56.4)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,118	92.1 (89.0 , 94.3)	91.4 (64.6 , 98.2)	93.5 (90.2 , 95.7)	88.3 (82.3 , 92.3)			
2(b) 2.1.1. Mycosis fungoides	1,088	93.3 (90.1 , 95.5)	91.4 (64.6 , 98.2)	94.2 (90.9 , 96.3)	90.0 (83.9 , 93.9)			
2(b) 2.1.2. Sezary syndrome	30	42.7 (20.2 , 63.6)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2. Peripheral T-cell lymphoma	2,338	59.4 (56.9 , 61.7)	84.8 (75.3 , 90.8)	69.3 (66.3 , 72.1)	43.4 (39.2 , 47.5)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	752	38.9 (34.8 , 43.0)	- (- , -)	48.2 (42.4 , 53.8)	28.1 (22.1 , 34.3)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	357	47.0 (40.7 , 53.1)	- (- , -)	62.8 (53.5 , 70.7)	35.8 (27.7 , 44.1)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	45	91.1 (74.7 , 97.1)	- (- , -)	89.1 (67.2 , 96.7)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	444	63.4 (57.9 , 68.4)	82.9 (69.5 , 90.8)	71.5 (65.0 , 77.0)	32.6 (21.5 , 44.1)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	30	10.2 (2.0 , 26.6)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	466	83.9 (78.5 , 88.1)	- (- , -)	89.3 (83.6 , 93.1)	74.3 (63.4 , 82.4)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	228	90.4 (82.3 , 94.9)	- (- , -)	94.5 (87.5 , 97.6)	78.8 (56.5 , 90.5)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	374	51.8 (45.4 , 57.8)	81.6 (73.4 , 87.5)	34.4 (24.0 , 45.0)	20.9 (10.8 , 33.3)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	155	43.7 (33.7 , 53.3)	- (- , -)	48.2 (37.6 , 58.0)	37.1 (18.2 , 56.2)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	60	75.0 (58.6 , 85.7)	- (- , -)	82.4 (62.5 , 92.3)	63.8 (37.5 , 81.4)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	75	8.9 (2.1 , 22.2)	- (- , -)	13.5 (2.8 , 32.8)	6.4 (0.5 , 24.3)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	29	35.6 (18.7 , 53.0)	- (- , -)	- (- , -)	- (- , -)			
2(c) Non-Hodgkin lymphoma, unknown lineage	689	61.1 (56.8 , 65.2)	88.5 (82.3 , 92.7)	60.2 (52.3 , 67.3)	47.1 (40.6 , 53.3)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	269	67.6 (61.4 , 73.0)	89.7 (83.6 , 93.6)	40.9 (27.8 , 53.5)	21.9 (10.8 , 35.5)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	26	54.1 (28.4 , 74.1)	- (- , -)	- (- , -)	- (- , -)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	394	57.1 (50.9 , 62.9)	- (- , -)	69.2 (59.3 , 77.1)	51.5 (44.0 , 58.4)			
2(*) 1. Total precursor lymphoma/leukemia ^d	4,047	68.5 (66.9 , 70.1)	89.2 (87.7 , 90.6)	40.6 (37.3 , 43.9)	16.8 (12.5 , 21.6)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	46	55.4 (36.4 , 70.9)	- (- , -)	72.3 (45.4 , 87.6)	- (- , -)			
4 Lymphoid neoplasm, NOS ^c	2,010	51.1 (48.2 , 53.9)	84.3 (61.5 , 94.1)	67.4 (63.0 , 71.4)	42.1 (38.4 , 45.7)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.